Literature DB >> 2168443

Thyroid-stimulating antibody activity between different immunoglobulin G subclasses.

A P Weetman1, M E Yateman, P A Ealey, C M Black, C B Reimer, R C Williams, B Shine, N J Marshall.   

Abstract

To investigate the distribution of thyroid-stimulating antibody (TSAb) activity between IgG subclasses, sera from 11 patients with Graves disease (including the National Institute of Biological Standards and Control (NIBSC) Research Standard, long acting thyroid stimulator-B) were fractionated by chromatography on affinity columns of monoclonal IgG subclass antibodies or protein A to deplete all but a single subclass. The resulting fractions were 98% or more pure for a single subclass. In all 11 patients, TSAb activity appeared to be confined to the IgG1 fraction as determined by cAMP production on addition of the fractions to the FRTL-5 rat thyroid cell line. In all of eight specimens from seven patients so tested, the whole serum activity was recovered in the IgG1 fraction, after adjusting for the recovery of the isotype from the column. TSAb activity in one serum comprised both lambda and kappa light chains but was IgG1 restricted. This IgG subclass restriction was not found when the same fractions were tested for thyroglobulin, microsomal/thyroid peroxidase, or tetanus toxoid antibody activity. Together with previous results showing marked restriction of both light chain usage and isoelectric point of TSAb, these results support the idea that Graves' disease may be the result of an oligo- or possibly monoclonal response at the B cell level.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168443      PMCID: PMC296786          DOI: 10.1172/JCI114768

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  CHARACTERIZATION OF THE LONG-ACTING THYROID STIMULATOR OF GRAVES' DISEASE.

Authors:  J C MEEK; A E JONES; U J LEWIS; W P VANDERLAAN
Journal:  Proc Natl Acad Sci U S A       Date:  1964-08       Impact factor: 11.205

Review 2.  LATS in Graves' disease.

Authors:  J M McKenzie; M Zakarija
Journal:  Recent Prog Horm Res       Date:  1976

Review 3.  Immune mechanisms in Graves' disease.

Authors:  K D Burman; J R Baker
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

4.  Isoelectric focusing of thyroid-stimulating antibody of Graves' disease.

Authors:  M Zakarija; J M McKenzie
Journal:  Endocrinology       Date:  1978-10       Impact factor: 4.736

Review 5.  Biological activities of immunoglobulins of different classes and subclasses.

Authors:  H L Spiegelberg
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

6.  Immunochemical characterization of the thyroid-stimulating antibody (TSAb) of Graves' disease: evidence for restricted heterogeneity.

Authors:  M Zakarija
Journal:  J Clin Lab Immunol       Date:  1983-02

Review 7.  The thyrotrophin receptor.

Authors:  S W Manley; A Knight; D D Adams
Journal:  Springer Semin Immunopathol       Date:  1982

8.  The distribution of microsomal and thyroglobulin antibody activity among the IgG subclasses.

Authors:  A B Parkes; S M McLachlan; P Bird; B Rees Smith
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

Review 9.  Autoimmune thyroid disease: developments in our understanding.

Authors:  A P Weetman; A M McGregor
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

10.  Thyroid antibodies are produced by thyroid-derived lymphocytes.

Authors:  A P Weetman; A M McGregor; J H Lazarus; R Hall
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

View more
  26 in total

1.  Clonal relationships between thyroid-stimulating hormone receptor-stimulating antibodies illustrate the effect of hypermutation on antibody function.

Authors:  Carolyn J Padoa; Sanne L Larsen; Christiane S Hampe; Jacqueline A Gilbert; Elif Dagdan; Laszlo Hegedus; Deborah Dunn-Walters; J Paul Banga
Journal:  Immunology       Date:  2009-10-21       Impact factor: 7.397

Review 2.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

3.  Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease.

Authors:  Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Endocrinol Metab       Date:  2014-09-11       Impact factor: 5.958

Review 4.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

5.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 6.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

7.  Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines.

Authors:  R J Mullins; S B Cohen; L M Webb; Y Chernajovsky; C M Dayan; M Londei; M Feldmann
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Different fetal-neonatal outcomes in siblings born to a mother with Graves-Basedow disease after total thyroidectomy: a case series.

Authors:  Antonio Alberto Zuppa; Paola Sindico; Sabrina Perrone; Chiara Carducci; Eleonora Antichi; Giovanni Alighieri; Francesco Cota; Patrizia Papacci; Maria Pia De Carolis; Costantino Romagnoli; Valentina Cardiello
Journal:  J Med Case Rep       Date:  2010-02-19

Review 9.  A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocrine       Date:  2019-09-27       Impact factor: 3.633

10.  Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves' disease model.

Authors:  Q Yuan; Y Zhao; X Zhu; X Liu
Journal:  J Endocrinol Invest       Date:  2016-11-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.